


COVID-19 Vaccination Schedule

for Moderately to Severely Immunocompromised Patients

Includes blood cancer patients and most survivors

If you are moderately to severely immunocompromised, you are at increased risk of severe COVID-19 illness and death. Additionally, your immune response to vaccination may not be as strong as in people who are not immunocompromised, so additional vaccine doses are needed. Even after receiving all recommended vaccines, LLS encourages blood cancer patients to take additional precautions, like wearing a mask and social distancing.

As of September 2, 2022 there are two types of booster doses available. Updated (bivalent) boosters add Omicron-specific protection along with protection against the original COVID-19 strain. The bivalent vaccine is recommended for everyone 12 years and older regardless of their immune status. The original monovalent booster vaccines is still recommended for certain children younger than age 12 years until the updated booster becomes available for them.



The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.



Pfizer-BioNTech (Comirnaty) Ages 6 months - 4 years Ages **5 – 11 years** Ages 12 years and older **Primary Dose 1 Primary Dose 1 Primary Dose 1** Wait 3 weeks Wait 3 weeks Wait 3 weeks **Primary Dose 2 Primary Dose 2 Primary Dose 2** Additional primary dose for Additional primary dose for Additional primary dose for immunocompromised patients immunocompromised patients immunocompromised patients Wait at least Wait at least Wait at least 8 weeks 8 weeks 4 weeks **Primary Dose 3 Primary Dose 3 Primary Dose 3** Wait at least Wait at least A booster dose is not 2 months after 3 months recommended at this time. third primary dose or last Monovalent monovalent Booster booster Note: Only monovalent **Bivalent** Pfizer-BioNTech **Booster** booster is approved Note: For 18+ for this age group. can be either Pfizer-BioNTech or Moderna; for 12-17 can only be Pfizer-BioNTech

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.

COVID-19 Vaccination Schedule for Moderately to Severely Immunocompromised Patients

Novavax

Ages 12 years and older



Primary Dose 1





Primary Dose 2

Wait at least 2 months after second primary dose



Bivalent Booster

Note: For 18+ can be either Pfizer-BioNTech or Moderna; for 12-17 can only be Pfizer-BioNTech



Get vaccinated as recommended even if you had COVID-19



Keep practicing social distancing and masking



Talk to your healthcare team if unsure of your risk